G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
Authors' conclusion
Approximately 30% of body weight lost with GLP1Ra-based therapy is LM. More data are needed assessing BMD outcomes.
Study context
- Population
- Participants in RCTs reporting DXA-acquired lean mass (LM) or bone mineral density (BMD); mean (SD) age 41.7 (7.6) years, 75% female, BMI 30 to 43 kg/m²
- Participants
- 659 participants9 trials
- Comparison
- GLP-1 RA-based therapies vs placebo
- GLP1Ra-based therapiesn = 419
- Placebon = 240reference
- Outcome
- Change in DXA-acquired lean mass (LM) or BMD
- Follow-up
- 12+ weeks
Methodological detailsplacebo-controlled trials, hierarchical Bayesian model
- Placebo-controlled trials
- Hierarchical Bayesian model
Pooled result
As reported in the abstract
Change in DXA-acquired total body LM
Change in LM, GLP1Ra-based treatment vs placebo (significantly reduced; mean difference)
−1.9 kg
95% CrI −3.5 to −0.2
Further pooled results
| Outcome | Mean difference (kg) (95% CrI) | |
|---|---|---|
| Total body weight95% credible interval · CrI | −6.9 (−10.7 to −3.0) | |
| −15−10−505Difference, kg (linear scale) |
BMD
- BMD outcomes (2 trials) described narratively
Original publication
G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials. Obesity (Silver Spring). Published 22 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →